University of Kentucky Markey Cancer Center - Cancer Center Support Grant

简介（由申请人提供）：马基癌症中心（MCC）是一个专门的矩阵癌症中心，作为肯塔基大学（英国）和英国医疗保健企业的组成部分，在MCC主任B. Mark Evers博士的领导下，近年来经历了戏剧性的扩张。在中心发展的这一点上，MCC通过国家癌症研究所（NCI）癌症中心支持基金寻求支持，以利用这一势头，并通过癌症研究，预防和患者护理的综合计划，推动肯塔基州，特别是肯塔基州阿巴拉契亚地区癌症死亡率的显著降低。在一个在许多癌症指标上领先全国的州，包括全国最高的癌症死亡率，对NCI癌症中心指定的需求尤为迫切。MCC位于一个校园内，所有六所卫生专业学院彼此靠近，提供了丰富的跨学科历史

DESCRIPTION (provided by applicant): The Markey Cancer Center (MCC), a dedicated matrix cancer center established as an integral part of the University of Kentucky (UK) and the UK Healthcare enterprise, has undergone dramatic expansion in recent years under the leadership of MCC Director Dr. B. Mark Evers. At this point in the center's development, the MCC seeks support through the National Cancer Institute (NCI) Cancer Center Support Grant to capitalize on this momentum and to drive a measurable reduction in cancer mortality in Kentucky, particularly Appalachian Kentucky, through a comprehensive program of cancer research, prevention, and patient care. The need for NCI Cancer Center designation is particularly acute in a state that leads the nation across numerous cancer indicators, including the highest rate of cancer deaths in the nation. Situated on a campus with all six health professions colleges in proximity to each other, the MCC offers a history of rich transdisciplinary collaboration, an outstanding program of cancer prevention and control that has produced seminal work in Appalachian Kentucky, nationally acclaimed basic research programs in cancer biology and DNA repair and oxidative stress, and a translational therapeutics program complemented by a top five College of Pharmacy. These strengths have coalesced in MCC's four thematic research programs: Cancer Cell Biology and Signaling; Cancer Prevention and Control; Drug Discovery, Delivery and Translational Therapeutics; and Redox Injury and Repair. Currently, the MCC's 108 Research and Associate Research members hold appointments in 24 departments in 7 colleges across the university (25 new faculty were recruited in the last 3 years). MCC members hold grants for 144 research projects funded in the annual composite (direct + indirect) amount of more than $30.5 million, of which over $11.3 million (37%) comes from the NCI. Accrual to therapeutic clinical trials has increased over 130% in three years, and MCC assignable space has increased 40%, including a doubling of state-of-the-art research space. In addition, six shared resources facilitate cutting-edge research by providing a robust infrastructure for specialized expertise and advanced methods. They include: Biospecimen and Tissue Procurement; Biostatistics; Cancer Research Informatics; Clinical Research and Data Management; Flow Cytometry and Cell Sorting; and Free Radical Biology in Cancer. The MCC is currently well positioned to take on new challenges and to continue to evolve in key strategic directions that take maximum advantage of these strengths.